Daily non-political popular news in brief.

New drug helps hepatitis C patients start antiviral therapy

A new drug that stimulates the production of blood platelets can enable patients infected with hepatitis C virus to take other antiviral medications they previously could not take to fight the disease, according to the results of a clinical trial led by a Duke University Medical Center researcher.

Read more »

Keywords: drug, hepatitis, patients, start, antiviral, therapy, hepatiti, patient

« Previous | Next »

Similar news on "New drug helps hepatitis C patients start antiviral therapy":

1. Hepatitis B drug can compromise HIV treatment
   06-20-2007 · EurekAlert!
   Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal. In findings published in the New England Journal of Medicine, researchers reported that a patient infected with both hepatitis B and HIV who was treated with entecavir developed a mutant strain of HIV that is resistant to the antiviral drugs lamivudine and emtricitabine.
   Similar news · Read more »
   
2. Drug warning prompts treatment changes for those infected with hepatitis B and HIV
   06-20-2007 · EurekAlert!
   Cross-resistance alarms raised earlier this year by Johns Hopkins researchers about a widely used antiviral therapy for hepatitis B liver infections have prompted swift treatment revisions by the drug's maker and governmental agencies.
   Similar news · Read more »
   
3. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
   12-28-2007 · EurekAlert!
   For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease. This problem is compounded by the fact that standard antiviral treatment for the disease can further reduce platelet numbers to dangerously low levels, effectively denying these patients the treatment they urgently need. Now, research published in the New England Journal of Medicine finds that a new drug, eltrombopag, appears to significantly boost platelet counts, opening the door to effective treatment.
   Similar news · Read more »
   
4. 24-week course of interferon-alpha therapy prolongs survival in patients hepatitis C virus
   11-02-2007 · EurekAlert!
   A group at Hiroshima University Hospital performed a matched historical controlled study on whether a 24-week course of interferon-alpha therapy, after curative treatment for primary hepatocellular carcinoma associated with hepatitis C virus, could influence tumor recurrence, patient survival, and liver function. Patients with sustained virological responses had reduced recurrence, prolonged survival and a preserved liver function. The group also determined that viral eradication was the most important factor in such patients.
   Similar news · Read more »
   
5. Silymarin does not affect virus activity or ALT levels in
   02-01-2008 · EurekAlert!
   In a survey of patients with chronic hepatitis C who participated in a National Institute of Diabetes and Digestive and Kidney Diseases-sponsored long-term treatment trial for patients who had failed to respond previously to antiviral therapy, approximately 40 percent acknowledged to interviewers at the time of enrollment that they were currently using or had in the recent past used herbal products for health purposes.
   Similar news · Read more »
   
6. Gene patenting -- steep cost for health care and patients
   05-07-2007 · EurekAlert!
   The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
   Similar news · Read more »
   
7. Hepatitis B patients' understanding of infection and treatment deficient
   05-24-2007 · EurekAlert!
   Many patients with chronic hepatitis B are deficient in their understanding of the lifelong disease and often do not comply with the drug regimens necessary to control it, according to a new UCLA survey that suggests improved patient involvement in disease management decisions could be the key to fixing this problem.
   Similar news · Read more »
   
8. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
   01-31-2008 · EurekAlert!
   Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
   Similar news · Read more »
   
9. Widely used hepatitis B drug spurs HIV drug resistance
   02-28-2007 · EurekAlert!
   A Johns Hopkins study has proven false established medical practice that an antiretroviral drug widely used to treat hepatitis B liver infections was safe to use on its own in patients co-infected with HIV. Their findings demonstrate that treatment with entecavir leads to cross-resistance to other antiviral drugs used to treat the AIDS virus.
   Similar news · Read more »
   
10. Hepatitis C treatment reduces the virus but serious liver problems may progress
    11-06-2007 · EurekAlert!
    Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon. However, the treatment did not slow or prevent the progression of serious liver disease. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis, and were reported at the annual meeting of the American Association for the Study of Liver Disease
    Similar news · Read more »